CA3059225A1 - Antifungal agents used in combination - Google Patents
Antifungal agents used in combination Download PDFInfo
- Publication number
- CA3059225A1 CA3059225A1 CA3059225A CA3059225A CA3059225A1 CA 3059225 A1 CA3059225 A1 CA 3059225A1 CA 3059225 A CA3059225 A CA 3059225A CA 3059225 A CA3059225 A CA 3059225A CA 3059225 A1 CA3059225 A1 CA 3059225A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic agent
- pharmaceutical combination
- subject
- formula
- amphotericin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483647P | 2017-04-10 | 2017-04-10 | |
| US62/483,647 | 2017-04-10 | ||
| PCT/US2018/026088 WO2018191077A1 (en) | 2017-04-10 | 2018-04-04 | Antifungal agents used in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059225A1 true CA3059225A1 (en) | 2018-10-18 |
Family
ID=62063223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059225A Pending CA3059225A1 (en) | 2017-04-10 | 2018-04-04 | Antifungal agents used in combination |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11110102B2 (https=) |
| EP (1) | EP3609539A1 (https=) |
| JP (2) | JP7263313B2 (https=) |
| KR (2) | KR20240110109A (https=) |
| CN (1) | CN110769854B (https=) |
| AR (1) | AR113221A1 (https=) |
| AU (1) | AU2018253031B2 (https=) |
| CA (1) | CA3059225A1 (https=) |
| EA (1) | EA201992413A1 (https=) |
| MA (1) | MA49889A (https=) |
| MX (1) | MX2019012116A (https=) |
| TW (1) | TWI806861B (https=) |
| WO (1) | WO2018191077A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102807716B1 (ko) * | 2017-08-04 | 2025-05-13 | 싸이넥시스, 인크. | 산성 pH에서 증진된 활성을 갖는 항진균제 |
| BR112021016876A2 (pt) * | 2019-02-27 | 2021-11-03 | Scynexis Inc | Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto |
| AU2020276595B2 (en) * | 2019-05-16 | 2025-12-04 | Scynexis, Inc. | Antifungal Agents for Candida Auris Decolonization |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| WO2010019204A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Antifungal agents |
| KR101686075B1 (ko) * | 2008-08-12 | 2016-12-13 | 싸이넥시스, 인크. | 항균제 |
| CA2982660C (en) * | 2014-11-21 | 2023-01-24 | F2G Limited | 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents |
| HRP20220544T1 (hr) | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
-
2018
- 2018-04-04 MA MA049889A patent/MA49889A/fr unknown
- 2018-04-04 US US15/945,428 patent/US11110102B2/en active Active
- 2018-04-04 CA CA3059225A patent/CA3059225A1/en active Pending
- 2018-04-04 JP JP2020504267A patent/JP7263313B2/ja active Active
- 2018-04-04 WO PCT/US2018/026088 patent/WO2018191077A1/en not_active Ceased
- 2018-04-04 AU AU2018253031A patent/AU2018253031B2/en active Active
- 2018-04-04 CN CN201880033777.4A patent/CN110769854B/zh active Active
- 2018-04-04 EP EP18720489.6A patent/EP3609539A1/en active Pending
- 2018-04-04 MX MX2019012116A patent/MX2019012116A/es unknown
- 2018-04-04 KR KR1020247022473A patent/KR20240110109A/ko active Pending
- 2018-04-04 EA EA201992413A patent/EA201992413A1/ru unknown
- 2018-04-04 KR KR1020197032870A patent/KR102683355B1/ko active Active
- 2018-04-09 AR ARP180100881A patent/AR113221A1/es not_active Application Discontinuation
- 2018-04-10 TW TW107112305A patent/TWI806861B/zh active
-
2021
- 2021-08-10 US US17/399,015 patent/US20220202833A1/en active Pending
-
2022
- 2022-12-22 JP JP2022205904A patent/JP7574268B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI806861B (zh) | 2023-07-01 |
| TW201842915A (zh) | 2018-12-16 |
| US20220202833A1 (en) | 2022-06-30 |
| KR20240110109A (ko) | 2024-07-12 |
| EA201992413A1 (ru) | 2020-03-16 |
| AU2018253031A1 (en) | 2019-10-31 |
| AR113221A1 (es) | 2020-02-19 |
| JP7263313B2 (ja) | 2023-04-24 |
| KR102683355B1 (ko) | 2024-07-10 |
| JP2020513037A (ja) | 2020-04-30 |
| AU2018253031B2 (en) | 2024-04-11 |
| US11110102B2 (en) | 2021-09-07 |
| CN110769854B (zh) | 2023-01-13 |
| MX2019012116A (es) | 2019-11-21 |
| JP2023030113A (ja) | 2023-03-07 |
| KR20190133251A (ko) | 2019-12-02 |
| JP7574268B2 (ja) | 2024-10-28 |
| EP3609539A1 (en) | 2020-02-19 |
| CN110769854A (zh) | 2020-02-07 |
| US20180325919A1 (en) | 2018-11-15 |
| BR112019021138A2 (pt) | 2020-05-12 |
| MA49889A (fr) | 2020-06-24 |
| WO2018191077A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7574268B2 (ja) | 併用される抗真菌剤 | |
| US20260000656A1 (en) | Antifungal agents with enhanced activity in acidic ph | |
| EP3917534B1 (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections | |
| BR112019021138B1 (pt) | Combinação farmacêutica, e, uso de uma combinação farmacêutica | |
| HK40022879B (en) | Antifungal agents used in combination | |
| HK40022879A (en) | Antifungal agents used in combination | |
| HK40091926A (en) | Antifungal agents with enhanced activity in acidic ph | |
| EA047299B1 (ru) | Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких | |
| HK40030410B (en) | Antifungal agents with enhanced activity in acidic ph | |
| HK40030410A (en) | Antifungal agents with enhanced activity in acidic ph | |
| HK40062374A (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections | |
| HK40062374B (en) | Triterpenoid antifungals for the treatment of fungal osteo-articular infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230313 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240926 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250324 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251030 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251030 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260309 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260309 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260331 |